Could This Be The Biggest Biotech Breakthrough Of The Decade? (SPONSORED POST)

TM editors' note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

A little-known, visionary biotech company is gearing up to release a potentially ground-breaking medical device that could help prevent strokes. It could help save six million lives a year—or a life every 4 minutes.

The unique new technology is the Carotid Stenotic Scan (CSS), by CVR Medical, and its futuristic system is designed to sense the leading indicator of strokes in only 2 minutes, and at a cost that will make it affordable and accessible to everyone.

CVR Medical (TSX:CVM.V ; OTC:CRRVF) is ready to burst out of the gate directly into a massive market. Here’s why:

  • This is unprecedented: Pre-stroke intervention has never before been affordable and accessible

  • It’s not invasive and preliminary tests demonstrate that in most cases it takes only 2 minutes

  • The patented technology is positioned to own this huge market segment

  • A CSS unit costs roughly $49,000, while current technology costs up to $2.5 million, making it economically out of reach

  • Over 230,000 medical facilities in the U.S. alone could potentially want the device, and globally the demand could be huge

  • The visionary team has invested $23 million in development and is expecting preliminary clinical results any day now

For the First Time in History: An Affordable Solution to a Multi-Billion-Dollar Problem

Stroke statistics are shocking: Globally, every year 15 million people suffer a stroke. In the U.S. alone, nearly 800,000 people suffer from a stroke annually.

Currently, one out of every 20 deaths in America is caused by stroke, making this one of the most pressing medical problems of our time.

Until now, there has been no cost-effective way to screen for the leading indicator of Ischemic strokes, which cost the U.S. government alone over 30 billion dollars a year in healthcare expenses.

1 2 3 4
View single page >> |

Legal Disclaimer/Disclosure: This piece is an advertorial and has been paid for. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Jimmy Richards 3 years ago Member's comment

I will be taking a closer look at $CRRVF, thanks.

George Lipton 3 years ago Member's comment

This looks very promising. Are there any downsides that people can see about investing in $CRRVF?

David P. Goldsmith 3 years ago Member's comment

I love learning about these hidden gems on TalkMarkets. $CRRVF

IB Trading 3 years ago Member's comment

Good post, thanks for sharing.

Carl Schwartz 3 years ago Member's comment

This sounds potentially (to quote Trump) HUGE!

Gary Tanashian 3 years ago Contributor's comment

Excellent concept. I've seen story stocks on the TSX-V before, and they often remain just stories. Did a little quick research on Bakema and his patents and it looks good. Still, the penny stock aspect begs in-depth personal research IMO.

Carol Klein 3 years ago Member's comment

Yes, though I don't like some of the vague wording here. E.g. "Expecting results any day now" or "demand could be huge." I would have liked to see more concrete numbers. But overall my interest is certainly piqued.

Harry Goldstein 3 years ago Member's comment

Have to agree with you 100% Gary. Would greatly appreciate it if others share what they learn about this company.